The nearly 300% YoY unit sales growth is a positive operational signal for a micro-cap diagnostics company, but the lack of dollar-based revenue figures and the company's $1M market cap limit the near-term trading impact. Monitor the next quarterly filing for actual revenue and cash flow data to validate whether this volume growth translates into financial improvement.
Price Chart
Executive Summary
bioAffinity Technologies announced via an 8-K that unit sales of its CyPath Lung diagnostic test reached a record monthly high in April 2026, increasing nearly 300% compared to April 2025, based on preliminary unaudited data. The filing is a routine operational update with no financial statements or guidance provided.
Key Facts
- CyPath Lung unit sales in April 2026 increased nearly 300% year-over-year versus April 2025.
- The data is preliminary and unaudited.
- The company has a market cap of approximately $1 million.
- No revenue, EPS, or other financial figures were disclosed in the filing.
Financial Impact
No dollar amounts disclosed; unit sales growth of nearly 300% YoY is a positive volume trend but from an undisclosed base.
Risk Factors
- Preliminary and unaudited data may be revised.
- No revenue or profitability figures provided; unit growth may not translate to positive cash flow.
- Company has a very small market cap ($1M) and is dependent on a single commercial product (CyPath Lung).
- Forward-looking statements about continued growth are not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022428 |
| Exhibit: ex99-1.htm | 0001493152-26-022428 |
| Document: 0001493152-26-022428-index-headers.html | 0001493152-26-022428 |
| Document: 0001493152-26-022428-index.html | 0001493152-26-022428 |
| Document: 0001493152-26-022428.txt | 0001493152-26-022428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.2950 $0.1300 | ▼ −55.93% | ▼ −54.37% | — |
May 27, 2026 21w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.90% | — |
May 13, 2026 23w ago | EFFECT | $0.2950 $0.2950 | · 0.00% | ▲ +0.61% | — |
May 12, 2026 23w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.73% | — |
May 8, 2026 24w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −0.02% | — |
Apr 14, 2026 27w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −6.30% | — |
Apr 7, 2026 28w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −9.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers